SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ArQule -- Ignore unavailable to you. Want to Upgrade?

To: tommysdad who wrote (333)5/6/1999 4:59:00 PM
From: Dr. John M. de Castro  Read Replies (1) | Respond to of 399
 
It did trip a milestone payment to ARQL. So it was a legitimate item to announce. But, I agree with you that it was not a biggie.

However, given all the negative speculation and the lack of information from the company for a good while, it is nice to see some positive developments, even if they aren't earth shaking.

John de C



To: tommysdad who wrote (333)5/12/1999 9:25:00 PM
From: StockDoc  Read Replies (1) | Respond to of 399
 
Entering preclinical tox studies indicates that the molecule(s) is manufactured under cGMP in and is going to be tested in people assuming that the PK/PD is favorable. Oherwise it is not a big deal - for Roche - indeed. For ArQule, this is the final deal or final product - i.e., big deal. They would need such things by the dozen to become what they wanted to be.
No molecule is worth $100 M before clinical testing.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News